Literature DB >> 7871034

Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug.

B M Migler1, E J Warawa, J B Malick.   

Abstract

Seroquel was compared to clozapine and several other antipsychotic agents in tests predictive of antipsychotic activity or extrapyramidal symptoms. In the conditioned avoidance test in squirrel monkeys as well as several paradigms using apomorphine or amphetamine-induced behavioral alterations, seroquel displayed the profile of a drug with potential antipsychotic activity. In these paradigms the potency of seroquel was somewhat less than clozapine in rodent tests, while the reverse was true in higher species, i.e. monkeys, cats. In tests designed to evaluate the propensity to induce EPS or tardive dyskinesia, for example, the production of dyskinetic reactions in haloperidol-sensitized cebus monkeys, seroquel displayed a profile similar to clozapine and disparate from typical antipsychotic drugs. In drug-naive cebus monkeys seroquel sensitized significantly fewer monkeys than haloperidol and the dyskinetic reactions were of significantly less intensity. It is anticipated that this novel antipsychotic agent will have a significantly reduced propensity to produce extrapyramidal symptoms and tardive dyskinesia than typical antipsychotics.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7871034     DOI: 10.1007/bf02244925

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  [Apomorphine synergism (inducedgnawing in mice) as a test for the differentiation of psychotropic substances].

Authors:  L THER; H SCHRAMM
Journal:  Arch Int Pharmacodyn Ther       Date:  1962-07-01

Review 2.  Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis.

Authors:  D Tarsy
Journal:  Clin Neuropharmacol       Date:  1983       Impact factor: 1.592

3.  Neuroleptics decrease blinking in schizophrenic subjects.

Authors:  C Karson; W J Freed; J E Kleinman; L B Bigelow; R J Wyatt
Journal:  Biol Psychiatry       Date:  1981-07       Impact factor: 13.382

4.  The AMDP system in international clinical trials: a double-blind comparison of fluperlapine and haloperidol.

Authors:  B Woggon; M Linden; H Beckmann; E Krebs; B Küfferle; B Müller-Oerlinghausen; B Pflug; H W Schied
Journal:  Psychopharmacol Bull       Date:  1986

5.  The risks and benefits of clozapine versus chlorpromazine.

Authors:  J Claghorn; G Honigfeld; F S Abuzzahab; R Wang; R Steinbook; V Tuason; G Klerman
Journal:  J Clin Psychopharmacol       Date:  1987-12       Impact factor: 3.153

6.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

7.  Pharmacological modification of experimental tardive dyskinesia.

Authors:  S Bárány; L M Gunne
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1979-08

8.  Catalepsy induced by SCH 23390 in rats.

Authors:  M Morelli; G Di Chiara
Journal:  Eur J Pharmacol       Date:  1985-11-05       Impact factor: 4.432

9.  Application of a primate model for tardive dyskinesia.

Authors:  S Bárány; J E Häggström; L M Gunne
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1983-02

Review 10.  Clozapine: neuroleptic-induced EPS and tardive dyskinesia.

Authors:  D E Casey
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

View more
  17 in total

Review 1.  Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

Authors:  E Stip
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  Effects of aripiprazole and clozapine on the treatment of glycolytic carbon in PC12 cells.

Authors:  Akira Ota; Akira Nakashima; Yoko S Kaneko; Keiji Mori; Hiroshi Nagasaki; Takeshi Takayanagi; Mitsuyasu Itoh; Kazunao Kondo; Toshiharu Nagatsu; Miyuki Ota
Journal:  J Neural Transm (Vienna)       Date:  2012-03-04       Impact factor: 3.575

3.  Seroquel: biochemical profile of a potential atypical antipsychotic.

Authors:  C F Saller; A I Salama
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Seroquel: electrophysiological profile of a potential atypical antipsychotic.

Authors:  J M Goldstein; L C Litwin; E B Sutton; J B Malick
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.

Authors:  Miho Tada; Kiyoharu Shirakawa; Nobuya Matsuoka; Seitaro Mutoh
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

6.  Quetiapine : A Review of its Use in Schizophrenia.

Authors:  N S Gunasekara; C M Spencer
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

7.  Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective "D1-like" dopamine receptor agonist A 68930 and selective "D2-like" agonist RU 24213.

Authors:  A M Deveney; J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

8.  Differential effect of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics.

Authors:  T Skarsfeldt
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 9.  Quetiapine for schizophrenia.

Authors:  M Srisurapanont; B Maneeton; N Maneeton
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 10.  Quetiapine versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Franziska Schmid; Heike Hunger; Sandra Schwarz; Manit Srisurapanont; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.